SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Company Response from Karyopharm Therapeutics (KPTI) — May 12, 2026

Karyopharm Therapeutics Inc.
Date: May 12, 2026 · CIK: 0001503802 · Accession: 0001193125-26-219339

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-295533

Date
May 12, 2026
Author
By
Form
CORRESP
Company
Karyopharm Therapeutics Inc.

Letter

Re:

May 12, 2026 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Alan Campbell

Karyopharm Therapeutics Inc.

Registration Statement on Form S-3 Filed May 4, 2026 File No. 333-295533 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295533), so that it may become effective at 4:30 p.m., Eastern Time, on May 14, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

Very truly yours,
KARYOPHARM THERAPEUTICS INC.
By:

Show Raw Text
CORRESP
 1
 filename1.htm

 CORRESP

 May 12, 2026
 VIA EDGAR SUBMISSION Securities and Exchange
Commission Division of Corporation Finance, Office of Life Sciences
 100 F Street, NE Washington, DC 20549
 Attention: Alan Campbell

 Re:

 Karyopharm Therapeutics Inc.

 Registration Statement on Form S-3
 Filed May 4, 2026 File
 No. 333-295533 Request for Acceleration
 Ladies and Gentlemen: Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form
 S-3 (File No. 333-295533), so that it may become effective at 4:30 p.m., Eastern Time, on May 14, 2026, or as soon as practicable thereafter, or at such later
time as the Registrant or its counsel may orally request via telephone call to the staff.

 Very truly yours,
 KARYOPHARM THERAPEUTICS INC.

 By:

 /s/ Michael Mano

 Name:

 Michael Mano

 Title:

 Executive Vice President, Chief Legal Officer and Secretary

 cc:

 Jason Kropp, Sidley Austin LLP

 Craig Hilts, Sidley Austin LLP